vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $18.6M, roughly 1.0× Zeo Energy Corp.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -10.8%, a 10.0% gap on every dollar of revenue. On growth, Zeo Energy Corp. posted the faster year-over-year revenue change (-0.4% vs -25.7%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-15.8M). Over the past eight quarters, Zeo Energy Corp.'s revenue compounded faster (-4.0% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs ZEO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.6M |
| Net Profit | $-154.0K | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -11.8% |
| Net Margin | -0.8% | -10.8% |
| Revenue YoY | -25.7% | -0.4% |
| Net Profit YoY | 97.6% | -360.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | $18.7M | $18.1M | ||
| Q1 25 | $50.9M | $8.8M | ||
| Q4 24 | $38.1M | $18.6M | ||
| Q3 24 | $33.4M | $19.7M | ||
| Q2 24 | $25.1M | $14.8M | ||
| Q1 24 | $41.5M | $20.1M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | $-154.0K | $-2.4M | ||
| Q1 25 | $23.5M | $-6.4M | ||
| Q4 24 | $18.9M | $-435.3K | ||
| Q3 24 | $5.7M | $-424.3K | ||
| Q2 24 | $-6.5M | $-277.8K | ||
| Q1 24 | $13.8M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | -11.8% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | -6.9% | -15.8% | ||
| Q1 25 | 44.4% | -153.8% | ||
| Q4 24 | 46.4% | -6.0% | ||
| Q3 24 | 12.3% | -15.2% | ||
| Q2 24 | -33.7% | -18.0% | ||
| Q1 24 | 28.1% | -20.1% |
| Q4 25 | — | -10.8% | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | -0.8% | -13.3% | ||
| Q1 25 | 46.2% | -72.4% | ||
| Q4 24 | 49.6% | -2.3% | ||
| Q3 24 | 17.2% | -2.2% | ||
| Q2 24 | -26.0% | -1.9% | ||
| Q1 24 | 33.3% | -7.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | — | $1.11 | ||
| Q3 24 | — | $-0.08 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $119.9M | $5.3M |
| Total Assets | $175.1M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $49.0M | $68.7K | ||
| Q1 25 | $47.6M | $2.9M | ||
| Q4 24 | $38.1M | $5.6M | ||
| Q3 24 | $40.6M | $4.3M | ||
| Q2 24 | $43.2M | $5.3M | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $119.9M | $-59.4M | ||
| Q1 25 | $25.0M | $-23.1M | ||
| Q4 24 | $-456.0K | $-88.9M | ||
| Q3 24 | $-23.5M | $-39.3M | ||
| Q2 24 | $-31.2M | $-53.0M | ||
| Q1 24 | $-31.7M | $-173.0M |
| Q4 25 | — | $56.9M | ||
| Q3 25 | — | $58.5M | ||
| Q2 25 | $175.1M | $46.2M | ||
| Q1 25 | $98.5M | $47.4M | ||
| Q4 24 | $120.5M | $61.0M | ||
| Q3 24 | $139.0M | $47.1M | ||
| Q2 24 | $159.2M | $49.1M | ||
| Q1 24 | $184.7M | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $2.4M |
| Free Cash FlowOCF − Capex | $-15.8M | $2.3M |
| FCF MarginFCF / Revenue | -84.6% | 12.2% |
| Capex IntensityCapex / Revenue | 0.1% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-6.6M | ||
| Q2 25 | $-15.8M | $-2.3M | ||
| Q1 25 | $-21.0M | $-2.3M | ||
| Q4 24 | $-19.9M | $3.5M | ||
| Q3 24 | $-20.7M | $162.2K | ||
| Q2 24 | $-19.5M | $-2.2M | ||
| Q1 24 | $-26.0M | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | $-15.8M | $-2.7M | ||
| Q1 25 | $-21.2M | $-2.6M | ||
| Q4 24 | $-20.0M | $3.4M | ||
| Q3 24 | $-20.7M | $116.5K | ||
| Q2 24 | $-19.6M | $-2.3M | ||
| Q1 24 | $-26.2M | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | -84.6% | -15.0% | ||
| Q1 25 | -41.6% | -30.0% | ||
| Q4 24 | -52.5% | 18.2% | ||
| Q3 24 | -62.1% | 0.6% | ||
| Q2 24 | -78.2% | -15.6% | ||
| Q1 24 | -63.1% | -51.5% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 0.1% | 2.4% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.2% | 0.5% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
